MediciNova Completes Last Patient, Last Visit In The Double-Blind Portion Of COMBAT-ALS Phase 2B/3 Clinical Trial Evaluating MN-166 For The Treatment Of Amyotrophic Lateral Sclerosis

MediciNova has completed the last patient visit in the double-blind portion of its COMBAT-ALS Phase 2B/3 clinical trial evaluating MN-166 for amyotrophic lateral sclerosis (ALS), involving 234 participants across the U.S. and Canada. The company anticipates reporting topline results by the end of 2026, with the last patient visit marking a significant milestone in their lead clinical program. MN-166 has received Fast Track and Orphan Drug designations from the FDA and has shown a favorable safety profile in previous studies.